Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (29616)	12/14/1999 8:05:00 AM
From: Arthur Radley	Respond to of 32384

I hope you fellows are right. Remember, on Friday I made the LAST purchase that was posted for the day so I was adding with hopes that we would react with a bang UP. Also, for this issue of filing for early stage CTCl, if you look at this news release before the FDA met, you will see the headline stating that they filed for Early stage CTCL and then in the body of the release it refers to stage Ia, which I assume is a fairly early stage for this disease. As for the after market trades, I wouldn't put much faith in them as they are retail trades and our hopes are in the hands of "big boys" coming into the stock. As stated earlier...my fingers are crossed. Ligand Submits NDA for Targretin Gel for Treatment of Patients with Early Stage Cutaneous T-Cell Lymphoma Targretin(R) Gel Potentially the First Approved Topical Treatment For CTCL SAN DIEGO--(BW HealthWire)--Dec. 9, 1999-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Targretin(R) (bexarotene) gel 1%, a novel topical therapy for the treatment of cutaneous lesions in patients with Stage IA, IB or IIA cutaneous T-cell lymphoma (CTCL) who have not tolerated other therapies or who have refractory or persistent disease. The FDA has granted Targretin orphan drug designation for the treatment of patients with CTCL, and Ligand has requested priority review status of the NDA filing. If the Targretin gel NDA is granted priority review status, the FDA is expected to complete its review of the application within six months of the submission. If granted marketing clearance, Targretin